Georgia Department of Public Health Commissioner Dr. “We get about 80,000 doses a week, and that’s not all for a state with 11 million people,” Kathleen Tommy said Tuesday.
• CaseJohns Hopkins University figures show that the country averaged 250,052 new coronavirus cases a day on Tuesday, down 19% from the previous week, but Johns Hopkins University figures show.
• Hospitalized: Covid-1920 patients were in hospitals on Tuesday – a number that dropped for the first time in five consecutive days since the end of September, according to Covid tracking project data.
• Mortality: The country averaged 2,989 deaths a day last week, down from 10% a week earlier, according to Johns Hopkins.
Officials say they need more vaccines
But state and local officials are concerned that supply will not be enough to keep up the momentum.
The San Francisco Department of Public Health announced that if no additional allocations were made, supplies would be cut off by Thursday. New York City is set to begin the same day, Mayor Bill de Blasio said Tuesday.
“If we don’t get more vaccines quickly, we’ll have to cancel the appointment,” de Blasio said.
Due to their low dose of the vaccine, Baptist Health South Florida has canceled all vaccine appointments for anyone scheduled to receive the first dose from Wednesday.
Studies suggest vaccinated people are protected against known variants in the UK and South Africa
New research provides evidence that people vaccinated against coronavirus will be protected against at least some types.
The two teams tested two types of tests against blood, who received a full two-course dose of Moderna or Pfizer / Bioentech vaccine.
When changes to new forms of the virus – first appearing in Britain and second in South Africa – freed them from some of the immunizations induced by vaccination, they escaped altogether, the two teams reported separately.
Dr. of Rufffeller University. A team led by Michelle Nussenzweig tested plasma from 20 people who received two doses of Pfizer / Bioentech or Modern vaccines as part of a clinical trial. They found that the vaccine produced a strong response to antibodies, as well as cells that produced new antibodies over months or years.
“We measure their antibody responses to wild-type viruses. We then took their plasmas and measured them against variables,” Nussenzweg told CNN.
Different mutations of the virus got rid of some types of antibodies, but the bodies of the volunteers threw an army of different types of antibodies on the virus, the team reported in a print run – not a peer review – published online.
“When you start putting all these combinations of antibodies together, they can take care of the variables with what it means.” Although their impact was minimal, the overall response was overwhelming that it didn’t matter, he said.
“What we really want to do with these vaccines is to keep people away from the hospital. They are likely to ignore this,” Nussenzweig added.
Ultimately, vaccines should be updated – but the new mRNA vaccine created by Pfizer and Moderna can be replaced very quickly. “Should the vaccine be given?” He asked. “Probably – but that doesn’t mean they won’t be effective.”
Separately, Ugur Sahin, who helped discover Pfizer’s bayonet tech, was seen testing his vaccine for the first time in the UK. The team found “no biologically significant difference in neutralization activity,” they said in a print report. But they said, just in case, it would be “prudent” to start tweaking the vaccine.
CNN’s Christina Maxoris, Naomi Thomas, Jamie Lynch, K. Jones, Alexandra Mix, Elizabeth Cohen and Lure Ren Mascarenhas contributed to the report.
.
